Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure
Exicure CEO David Giljohann has been busy.
In the past couple of months, he’s rounded up two tranches of cash totaling $31.5 million from a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
